Antibody-based therapies have become well established over the past 20 years. They have become one of the most important and successful strategies for treating patients with many diseases that were previously untreatable. With new formats, technologies and methods being developed every year, the antibody industry is fast moving and can be difficult to keep up with.
In the 13 years that the European Antibody Congress has run, there have been countless breakthroughs, advancements and achievements that not only were showcased for the first time at the European Antibody Congress, but were also born out of collaborations and partnerships that were catalysed by, or initiated, at the European Antibody Congress.
Our mission, for every European Antibody Congress, is to bring you the very best speakers from big pharma, biotechs, academia and technology innovators to discuss with you the most exciting breakthroughs when it comes to the discovery and development of antibodies. Whether that’s the newest format of a cancer killing ADC, the most advanced screening technology for mAbs, or the clinical development of a bispecific with promises to treat Alzheimer’s disease, we want to give you access to all of this to grow your knowledge, grow your business, and grow your connections.
Over the years, the European Antibody Congress programme has grown from strength to strength. This year, we are adding more streams allowing us to focus more heavily on protein engineering, antibody R&D, CMC and developability and bioprocessing. Brand new topics include AI for antibody discovery, co-formulation of biologics, safety and toxicity, and orally bioavailable biologics.
As part of the Festival of Biologics, the European Antibody Congress will be co-located with World Biosimilar Congress, World Immunotherapy Congress and HPAPI World Congress. Attendees will have access to plenty of content across the 3 days and more networking opportunities than ever before with over 800+ leading industry professionals.
We look forward to welcoming you to Basel.